Precigen (PGEN) said Tuesday that the US Food and Drug Administration has approved its investigational new drug application to initiate the phase 1/1b test of PRGN-3007 in advanced hematological and solid tumors.
The first-in-human study will be conducted in collaboration with the H. Lee Moffitt Cancer Center & Research Institute, it said.
Price: 4.64, Change: +0.07, Percent Change: +1.42